| Literature DB >> 28365132 |
Nicholas L Syn1, Lingzhi Wang2, Edward Kai-Hua Chow3, Chwee Teck Lim4, Boon-Cher Goh5.
Abstract
Exosomes (versatile, cell-derived nanovesicles naturally endowed with exquisite target-homing specificity and the ability to surmount in vivo biological barriers) hold substantial promise for developing exciting approaches in drug delivery and cancer immunotherapy. Specifically, bioengineered exosomes are being successfully deployed to deliver potent tumoricidal drugs (siRNAs and chemotherapeutic compounds) preferentially to cancer cells, while a new generation of exosome-based therapeutic cancer vaccines has produced enticing results in early-phase clinical trials. Here, we review the state-of-the-art technologies and protocols, and discuss the prospects and challenges for the clinical development of this emerging class of therapeutics.Entities:
Keywords: cancer nanomedicine; cancer vaccines; drug delivery; exosomes; extracellular vesicles; immunotherapy
Mesh:
Substances:
Year: 2017 PMID: 28365132 DOI: 10.1016/j.tibtech.2017.03.004
Source DB: PubMed Journal: Trends Biotechnol ISSN: 0167-7799 Impact factor: 19.536